Marlio Charles Mosseri Buys 5,603 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri bought 5,603 shares of the business’s stock in a transaction on Friday, June 20th. The stock was purchased at an average cost of $7.99 per share, for a total transaction of $44,767.97. Following the transaction, the insider now owns 2,981,806 shares of the company’s stock, valued at $23,824,629.94. This trade represents a 0.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Wednesday, June 18th, Marlio Charles Mosseri purchased 28,043 shares of Nuvectis Pharma stock. The shares were purchased at an average price of $8.05 per share, with a total value of $225,746.15.
• On Tuesday, June 17th, Marlio Charles Mosseri acquired 5,399 shares of Nuvectis Pharma stock. The stock was purchased at an average price of $8.11 per share, for a total transaction of $43,785.89.
• On Monday, May 12th, Marlio Charles Mosseri bought 21,167 shares of Nuvectis Pharma stock. The shares were purchased at an average cost of $8.11 per share, for a total transaction of $171,664.37.
• On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.65 per share, with a total value of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri purchased 12,444 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $8.59 per share, for a total transaction of $106,893.96.

Nuvectis Pharma Price Performance

NVCT stock opened at $7.98 on Wednesday. The business’s 50-day moving average is $9.22 and its two-hundred day moving average is $7.74. The firm has a market capitalization of $166.73 million, a P/E ratio of -7.06 and a beta of -0.16. Nuvectis Pharma, Inc. has a 1 year low of $4.44 and a 1 year high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. On average, analysts expect that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Nuvectis Pharma during the 1st quarter worth $413,000. Goldman Sachs Group Inc. acquired a new stake in Nuvectis Pharma in the first quarter valued at $446,000. OMERS ADMINISTRATION Corp purchased a new stake in Nuvectis Pharma during the 1st quarter worth about $321,000. Austin Wealth Management LLC acquired a new position in shares of Nuvectis Pharma during the 1st quarter worth about $393,000. Finally, Iridian Asset Management LLC CT purchased a new position in shares of Nuvectis Pharma in the 1st quarter valued at about $2,481,000. Institutional investors and hedge funds own 96.77% of the company’s stock.

Analysts Set New Price Targets

NVCT has been the subject of several recent research reports. Wall Street Zen raised shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research note on Saturday. Maxim Group assumed coverage on shares of Nuvectis Pharma in a report on Wednesday, April 2nd. They set a “buy” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target (up previously from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th. Finally, Laidlaw started coverage on Nuvectis Pharma in a research report on Monday, March 17th. They set a “buy” rating and a $19.00 price objective on the stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.